Already Registered? Log In Now Not Registered?
Complete this form to enter the webcast. Already Registered?

(* indicates required field)

Complete this form to enter the webcast.
(* indicates required field)

  • Oncology
  • Vaccine development
  • Cell and gene therapy
  • Rare disease
  • Infectious Disease
  • Other


*Denotes required.


Capping and manufacturing strategies to increase mRNA potency and reduce costs

This event is now available on demand!

Event Overview:

The emergence of mRNA as a versatile platform for vaccine development holds immense promise beyond COVID-19. An essential part of any mRNA vaccine is the 5’ cap structure, which is critical to the stability and expression of an mRNA. This presentation will explore the impact of 5’ cap on the functions and properties of mRNA and provide an overview of the latest developments in mRNA capping technology. By understanding the critical attributes of 5' cap structures and employing innovative capping strategies, mRNA drug developers can enhance manufacturing efficiency, reduce costs, and streamline the manufacturing process of mRNA-based medicines. This accelerates the development of novel mRNA-based vaccines and offers new hope for patients worldwide.

Key Learning Objectives:
  • Understand the potential of mRNA vaccines beyond COVID-19.
  • Gain insights into the functions and properties of mRNA with different 5' cap structures.
  • Identify how improved capping strategies can benefit mRNA vaccine development.
Who Should Attend:
  • mRNA drug developers and professionals from biotechnology, emerging biopharma, manufacturing services, and small to large pharrma
  • mRNA scientists in higher education or academia


Featured Speaker

Chunping Xu, PhD
Chunping Xu, PhD
Senior Director of Chemistry R&D
TriLink BioTechnologies


Chunping Xu, PhD, is the Senior Director of Chemistry R&D at TriLink Biotechnologies, where she oversees the development of novel CleanCap® analogs for improved protein expression and process optimization for modified NTPs. In addition, she and her team are investigating how to increase mRNA stability with various chemical modifications. Leveraging expertise in nucleotide chemistry, Dr. Xu and her team have created a library of over 100 novel cap analogs to identify next-generation CleanCap® analogs. Before joining TriLink, she had extensive experience in small molecule drug development and conjugation.


For any technical questions please contact Kristina Dunphey: Kdunphey@mjhevents.com